US2013296360A1PendingUtilityA1
Benzoquinoline inhibitors of vesicular monoamine transporter 2
Est. expirySep 18, 2028(~2.1 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 25/16A61P 25/14A61P 25/18A61P 25/00A61P 1/16A61P 21/00A61K 45/06C07B 59/002A61K 31/4745C07B 2200/05C07D 455/06C07B 59/00
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound of structural Formula I
or a salt thereof, wherein:
R 1 -R 27 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R 1 -R 27 is deuterium.
2 . The compound as recited in claim 1 wherein at least one of R 1 -R 27 independently has deuterium enrichment of no less than about 10%.
3 . The compound as recited in claim 1 wherein at least one of R 1 -R 27 independently has deuterium enrichment of no less than about 50%.
4 . The compound as recited in claim 1 wherein at least one of R 1 -R 27 independently has deuterium enrichment of no less than about 90%.
5 . The compound as recited in claim 1 wherein at least one of R 1 -R 27 independently has deuterium enrichment of no less than about 98%.
6 . The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of
7 . The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of
8 . The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 10%.
9 . The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 50%.
10 . The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 90%.
11 . The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 98%.
12 . The compound as recited in claim 7 wherein said compound has the structural formula:
13 . The compound as recited in claim 7 wherein said compound has the structural formula:
14 . A pharmaceutical composition comprising a compound as recited in claim 1 together with a pharmaceutically acceptable carrier.
15 . A compound having the structural formula:
or a salt thereof.
16 . The compound as recited in claim 15 wherein each position represented as D has deuterium enrichment of no less than about 10%.
17 . The compound as recited in claim 15 wherein each position represented as D has deuterium enrichment of no less than about 50%.Join the waitlist — get patent alerts
Track US2013296360A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.